Search





Search





Markets
/
Stocks
/
nasdaq-eton
/

Eton Pharmaceuticals Inc

ETON

Add to Watchlist

30.260USD

+0.300+1.00%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

827.91MMarket Cap

LossP/E TTM



Eton Pharmaceuticals Inc

30.260

+0.300+1.00%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Eton Pharmaceuticals Inc

Currency: USD Updated: 2026-05-15

Key Insights

Eton Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 39.33.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eton Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

40 / 155

Overall Ranking

111 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Eton Pharmaceuticals Inc Highlights

StrengthsRisks

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 152.67% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 79.95M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 79.95M.

Undervalued

The company’s latest PE is -544.54, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 15.99M shares, decreasing 18.71% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 2.80K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

41.000

Target Price

+36.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Eton Pharmaceuticals Inc is 7.68, ranking 93 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 24.27M, representing a year-over-year increase of 40.41%, while its net profit experienced a year-over-year increase of 198.85%.

Score

Industry at a Glance

Previous score

7.68

Change



Financials

8.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.99

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.57

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Eton Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Eton Pharmaceuticals Inc is 7.37, ranking 73 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -544.54, which is -119.01% below the recent high of 103.51 and -29.56% above the recent low of -705.51.

Score

Industry at a Glance

Previous score

7.37

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 40/155

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Eton Pharmaceuticals Inc is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 29.00, with a high of 35.00 and a low of 26.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

41.000

Target Price

+36.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Eton Pharmaceuticals Inc

ETON

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Eton Pharmaceuticals Inc is 9.49, ranking 12 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 34.21 and the support level at 24.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.39

Change

0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.258

Buy

RSI(14)

64.694

Neutral

STOCH(KDJ)(9,3,3)

53.011

Sell

ATR(14)

1.841

High Vlolatility

CCI(14)

31.233

Neutral

Williams %R

22.829

Buy

TRIX(12,20)

1.049

Sell

StochRSI(14)

19.270

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

30.118

Buy

MA10

30.195

Buy

MA20

27.229

Buy

MA50

24.520

Buy

MA100

20.385

Buy

MA200

18.998

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Eton Pharmaceuticals Inc is 5.00, ranking 73 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 58.43%, representing a quarter-over-quarter decrease of 4.32%. The largest institutional shareholder is James Simons, holding a total of 163.32K shares, representing 0.60% of shares outstanding, with 41.58% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Opaleye Management Inc.

2.86M

EcoR1 Capital, LLC

2.03M

BlackRock Institutional Trust Company, N.A.

1.57M

+0.64%

Nantahala Capital Management, LLC

1.18M

Brynjelsen (Sean E)

853.19K

-0.58%

Geode Capital Management, L.L.C.

565.05K

-1.56%

State Street Investment Management (US)

501.93K

+14.48%

Westside Investment Management, LLC

470.94K

-0.34%

Oberweis Asset Management, Inc.

431.30K

+124.22%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Eton Pharmaceuticals Inc is 5.75, ranking 62 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Eton Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.